INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms' Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies
Response Duration >2 Years Observed in a Patient with Plasma Cell Leukemia Findings Reported at American Society of Hematology (ASH) Annual Meeting 2015 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on
View HTML
Toggle Summary Atara Biotherapeutics Announces Third Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today reported
View HTML
Toggle Summary Atara Bio's Collaborating Investigators to Present Data From Two Cellular Therapy Product Candidates at the American Society of Hematology (ASH) Annual Meeting 2015
Presentations Include Clinical and Preclinical Results in Oncology and Virus-Associated Diseases
View HTML
Toggle Summary Atara Biotherapeutics Announces Participation in Three Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced its
View HTML
Toggle Summary Atara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements
Atara Bio Complements Its Cytotoxic T-Cell Programs to Develop Potential Additional Treatments for Certain Cancers and Autoimmune Disorders
View HTML
Toggle Summary Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that
View HTML
Toggle Summary Atara Bio to Host Investor Day on October 21, 2015
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc., (Nasdaq:ATRA), today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, October 21, 2015 at 12:00p.m. ET in New York, NY.
View HTML
Toggle Summary Atara Bio's PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet
Preclinical Data Published in the International Journal of Obesity
View HTML
Toggle Summary Atara Bio's Collaborating Investigators to Present Data at the American Society of Nephrology Kidney Week 2015
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Baylor College of
View HTML
Toggle Summary Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia
Data Presented at the 15th International Myeloma Workshop
View HTML